Nuffield Health and Australian radiotherapy provider GenesisCare have formed a partnership to develop oncology treatment services within Nuffield hospitals.
The SpaceOAR hydrogel procedure, a treatment for patients with prostate cancer that helps reduce the side-effects of radiotherapy, will be available to patients at Manor Hospital Oxford, Nuffield Leicester Hospital, Nuffield Tunbridge Wells Hospital, Nuffield Chichester Hospital, Nuffield North Staffordshire Hospital and Nuffield Wolverhampton Hospital.
The procedure involves a biodegradable water-based hydrogel being injected into the body before radiotherapy treatment, to reduce the radiation dose to nearby tissues.
By the end of the year a further nine Nuffield hospitals will be offering the minimally invasive procedure, according to the not-for-profit provider of health and wellbeing services.
As well as co-designing and implementing cancer care pathways – which includes expanding operations and improving access in under-served regions of the UK – the two organisations say they will be exploring investment opportunities for oncology treatment, diagnostics and other holistic services.
Chris Blackwell-Frost, chief customer officer at Nuffield Health, said: ‘This is the start of a really exciting collaboration. With our unique structure and not-for-profit model, Nuffield Health is perfectly placed to reach more patients across the UK with innovative and life changing cancer diagnostics and treatments.’
Aldo Rolfo, GenesisCare’s executive manager of Europe, added: ‘The partnership will enable us to lead the way in innovation, and open up access to the latest medical technology for people with cancer. Finding out that you or a loved one has cancer can be incredibly challenging, and we look forward to co-designing care experiences that get the best possible outcomes for our patients.’